Angiotensin-neprilysin inhibition versus enalapril in heart failure
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. CONCLUSIONS: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“showed superior efficacy of ARNI therapy over enalapril in chronic HF patients already receiving maximally tolerated dose of a renin-angiotensin system inhibitor (RASi).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [5]
In the citing paper
“Neprilysin inhibition does not seem to add to this effect.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“Neprilysin inhibition needs to be studied further, but does not seem to enhance this effect.224”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Cited by
Items 701–800 of 1,026
Oikonomou, E., Vogiatzi, G., Karlis, D., Siasos, G., Chrysohoou, C., Zografos, T., Lazaros, G., Tsalamandris, S., Mourouzis, K., Georgiopoulos, G., et al. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.04.017 · Cited by 61
Distinct submembrane localisation compartmentalises cardiac NPR1 and NPR2 signalling to cGMP
Subramanian, H., Froese, A., Jönsson, P., Schmidt, H., Gorelik, J., & Nikolaev, V. O. (2018) · Nature Communications · doi:10.1038/s41467-018-04891-5 · Cited by 61
Sex Differences in Heart Failure
Savarese, G., & D’Amario, D. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77932-4_32 · Cited by 77
Spannella, F., Marini, M., Giulietti, F., Rosettani, G., Francioni, M., Perna, G. P., & Sarzani, R. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-019-02111-6 · Cited by 61
“In the PARADIGM-HF trial, the first-in-class angiotensin receptor-neprilysin inhibitor Sacubitril/Valsartan, that combines the benefits derived from the inhibition of both the RAAS and the degradation of cardiac NPs, was found to reduce the risk of cardiovascular (CV) death and hospitalization due to HFrEF by 20%, com…”
BackgroundMethodInfluentialMarsault, É., Llorens‐Cortés, C., Iturrioz, X., Chun, H. J., Lesur, O., Oudit, G. Y., & Auger‐Messier, M. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14123 · Cited by 69
The Treatment of Heart Failure with Reduced Ejection Fraction
Berliner, D., Hänselmann, A., & Bauersachs, J. K. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0376 · Cited by 78
cGMP Signaling and Modulation in Heart Failure
Blanton, R. M. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000749 · Cited by 62
Yu, B., Sladojević, N., Blair, J. E., & Liao, J. K. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1712593 · Cited by 66
“benefit’ over standard therapy of care in patients with HFrEF and New York Heart Association Class II, III, and IV heart failure symptoms by a median follow-up of 27 months [106].”
Abraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G. S., Lindenfeld, J. M., Mehran, R., Ambardekar, A. V., Carson, P. E., Jacob, R., Januzzi, J. L., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2018 · Cited by 70
“Although early clinical trials of HFrEF variably defined a reduced LVEF as ≤ 30-45%, the common definition is currently an LVEF ≤ 40% (10,12-16).”
BackgroundSelf-citationAblation of lncRNA Miat attenuates pathological hypertrophy and heart failure
Liu, Y., Deng, J., Ma, W., Qiao, A., Xu, S., Yu, Y., Boriboun, C., Xiang, K., Han, D., Erñst, P., et al. (2021) · Theranostics · doi:10.7150/thno.50990 · Cited by 64
“Although ACE inhibitors [37] /ARBs [38] /ARNI [39], β-blockers [40] and aldosterone antagonists [41] have been proven to improve the clinical outcome of HFrEF, none of them have shown remarkably beneficial effects in the treatment of HFpEF.”
BackgroundObstructive sleep apnea and stroke: The mechanisms, the randomized trials, and the road ahead
Javaheri, S., Peker, Y., Yaggi, H. K., & Bassetti, C. L. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101568 · Cited by 67
Judge, D. P., Alexander, K. M., Cappelli, F., Fontana, M., García‐Pavía, P., Gibbs, S. D., Grogan, M. A., Hanna, M. A., Masri, A., Maurer, M. S., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.042 · Cited by 72
Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials
Ibrahim, N. E., Gaggin, H. K., Konstam, M. A., & Januzzi, J. L. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002528 · Cited by 62
“In the PARADIGM-HF trial (Prospective Angiotensin–Neprilysin Inhibition Versus Enalapril in Heart Failure), patients were required to have a BNP of at least 150 pg/mL or an NT-proBNP of ≥600 pg/mL, or if they had been hospitalized for HF within the previous 12 months, a BNP of at least 100 pg/mL or an NT-proBNP of ≥40…”
BackgroundN -Terminal B-type Natriuretic Peptide in Heart Failure
Richards, M. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2017.08.004 · Cited by 62
Chia, Y. M. F., Teng, T. K., Tan, E. S. J., Tay, W. T., Richards, M., Chin, C. W. L., Shimizu, W., Park, S. W., Hung, C., Ling, L. H., et al. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003651 · Cited by 63
Kompa, A. R., Lu, J., Weller, T. J., Kelly, D. J., Krum, H., von Lueder, T. G., & Wang, B. H. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.01.077 · Cited by 61
McMurray, J. J. V., Docherty, K. F., de Boer, R. A., Hammarstedt, A., Kitzman, D. W., Kosiborod, M. N., Maria Langkilde, A., Reicher, B., Senni, M., Shah, S. J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065061 · Cited by 60
Self-citationAssessing quality-of-life outcomes in cardiovascular clinical research
Mark, D. B. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.10 · Cited by 68
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N., Skra, J., Valensi, P., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0357-x · Cited by 59
Auer‐Grumbach, M., Toegel, S., Schabhüttl, M., Weinmann, D., Chiari, C., Bennett, D., Beetz, C., Klein, D., Andersen, P. M., Böhme, I., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.07.008 · Cited by 59
Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus
Bahtiyar, G., Gutterman, D. D., & Lebovitz, H. E. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0809-4 · Cited by 64
Understanding acute heart failure: pathophysiology and diagnosis
Arrigo, M., Parissis, J., Akiyama, E., & Mebazaa, A. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw044 · Cited by 86
The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure
Bayés‐Genís, A., Núñez, J. E., Zannad, F. M., Ferreira, J. P., Anker, S. D., Cleland, J. G. F., Dickstein, K., Filippatos, G. S., Lang, C. C., Ng, L. L., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.057 · Cited by 61
“These advances have provided the rationale for current evidence-based treatments, including angiotensin-converting enzyme (ACE)-inhibition, beta-blockade, mineralocorticoid receptor antagonism, and more recently, sacubitril-valsartan (2-5).”
BackgroundInfluentialThe heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
Hein, A. M., Scialla, J. J., Edmonston, D. L., Cooper, L. B., DeVore, A. D., & Mentz, R. J. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.02.009 · Cited by 66
“(35) Robust trials with adequate safeguards are needed to confirm the potential benefits in patients with HFrEF and advanced CKD. Current guidelines do not comment on the use of ARNI therapy in those with CKD, but suggests the potential for renal insufficiency with this medication.”
BackgroundInfluentialNoncoding RNAs versus Protein Biomarkers in Cardiovascular Disease
Schulte, C., Barwari, T., Joshi, A., Zeller, T., & Mayr, M. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.02.001 · Cited by 63
Li, L., Lou, Q., Liu, G., Lv, J., Yun, F., Li, T., Yang, W. J., Zhao, H., Zhang, L., Bai, N., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173120 · Cited by 63
Alcaide-Aldeano, A., Garay, A., Alcoberro, L., Jiménez‐Marrero, S., Yun, S., Tajes, M., García‐Romero, E., Díez‐López, C., González‐Costello, J., Mateus-Porta, G., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041199 · Cited by 64
Packer, M., & Metra, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1857 · Cited by 61
Self-citationDimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., et al. (2020) · Trials · doi:10.1186/s13063-020-04334-x · Cited by 58
CPAP Treatment and Cardiovascular Prevention
Javaheri, S., Martínez‐García, M. Á., & Campos‐Rodríguez, F. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.04.092 · Cited by 63
Hypertension: Current trends and future perspectives
Hunter, P. G., Chapman, F. A., & Dhaun, N. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14825 · Cited by 93
“outcomes for patients with heart failure with a reduced ejection fraction.(82) This study led to the licensing of sacubitril/valsartan, marketed by Novartis as Entresto, for heart failure with a reduced”
BackgroundSchou, M., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Patel, S., Chinnakondepalli, K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.038 · Cited by 70
Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure
Guichard, J. L., Bonno, E. L., Nassif, M. E., Khumri, T. M., Miranda, D., Jonsson, O., Shah, H., Alexy, T., MACALUSO, G. P., Sur, J. P., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.05.017 · Cited by 66
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 159
Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure
Greene, S. J., Sabbah, H. N., Butler, J., Voors, A. A., Albrecht-Küpper, B. E., Düngen, H., Dinh, W., & Gheorghiade, M. (2015) · Heart Failure Reviews · doi:10.1007/s10741-015-9522-7 · Cited by 59
Meems, L. M. G., & Burnett, J. C. J. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.10.001 · Cited by 57
“The approval of a small molecule, Entresto (Novartis, East Hanover, New Jersey), for heart failure (HF) has provided momentum for drug discovery in CV and related fields (2).”
BackgroundCurrent Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction
Tam, M., Lee, R., CASCINO, T. M., Konerman, M. C., & Hummel, S. L. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0709-2 · Cited by 60
Seidelmann, S. B., Vardeny, O., Claggett, B. L., Yu, B., Shah, A. M., Ballantyne, C. M., Selvin, E., MacRae, C. A., Boerwinkle, E., & Solomon, S. D. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005257 · Cited by 58
Self-citationAngiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema
Stone, C. A., & Brown, N. J. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.04.006 · Cited by 65
Management protocols for chronic heart failure in India
Mishra, S., Mohan, J. C., Nair, T., Chopra, V., Harikrishnan, S., Guha, S., Ramakrishnan, S., Ray, S., Sethi, R., Samal, U. C., et al. (2017) · Indian Heart Journal · doi:10.1016/j.ihj.2017.11.015 · Cited by 70
Tobe, S. W., Stone, J. A., Anderson, T. J., Bacon, S., CHENG, A. Y. Y., Daskalopoulou, S. S., Ezekowitz, J. A., Grégoire, J. C., Gubitz, G. J., Jain, R., et al. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.180194 · Cited by 72
Comparing the Benefit of Novel Therapies Across Clinical Trials
Butler, J., Anstrom, K. J., Armstrong, P. W., & For the VICTORIA Study Group (2020) · Circulation · doi:10.1161/circulationaha.120.047086 · Cited by 58
One‐Year Mortality After Intensification of Outpatient Diuretic Therapy
Madelaire, C., Gustafsson, F., Stevenson, L. W., Kristensen, S. L., Køber, L., Andersen, J., D’Souza, M., Biering‐Sørensen, T., Andersson, C., Torp-Pedersen, C. T., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016010 · Cited by 59
“Nursing home 3906 (5) 2595 (5) 286 (6) 117 (4) 56 (6)”
Carnicelli, A., Lippmann, S., Greene, S. J., Mentz, R. J., Greiner, M. A., Hardy, N. C., Hammill, B. G., Shen, X., Yancy, C. W., Peterson, P. N., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.03.012 · Cited by 59
Savarese, G., Settergren, C., Schrage, B., Thorvaldsen, T., Löfman, I. H., Sartipy, U., Mellbin, L., Meyers, A., FARSANI, S. F. F., Brueckmann, M., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.04.068 · Cited by 76
Renal Denervation to Treat Heart Failure
Sharp, T. E., & Lefer, D. J. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-093431 · Cited by 59
“In the PARADIGM-HF study (62), sacubitril/valsartan reduced combine primary end points of cardiovascular death and hospital admission by 20% when compared to enalapril in 8,442 patients with HFrEF.”
BackgroundLam, C. S. P., Ferreira, J. P., Pfarr, E., Sim, D., Tsutsui, H., Anker, S. D., Butler, J., Filippatos, G. S., Pocock, S., Sattar, N. A., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab360 · Cited by 67
“Thus, worsening HF was more likely to be treated as an outpatient in Europe than in other regions.(15,16) These findings suggest that European physicians prefer to treat worsening HF as an outpatient rather than in a hospitalized setting.”
ResultSelf-citationReverse re-modelling chronic heart failure by reinstating heart rate variability
Shanks, J. A., Abukar, Y., Lever, N. A., Pachen, M., LeGrice, I. J., Crossman, D. J., Nogaret, A., Paton, J. F. R., & Ramchandra, R. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00911-0 · Cited by 63
“More recent drugs such as sacubitril/valsartan (Entresto) and dapagliflozin have utility in refractory patients [30, 31] but the improvements in ejection fraction remain modest [25].”
BackgroundCharacterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients
Kaye, D. M., Nanayakkara, S., Wang, B., Shihata, W., Marques, F. Z., Esler, M., Lambert, G. W., & Mariani, J. A. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.11.007 · Cited by 59
“For example, despite evidence for marked efficacy in HFrEF, neprilysin inhibition has been shown to benefit only a subset HFpEF patients with left ventricular ejection fraction (LVEF) at the lower range of normal.(3,4) Recently, sodium-glucose transport protein 2 inhibitors were shown to exert favorable effects in HFp…”
BackgroundThe need for increased pragmatism in cardiovascular clinical trials
Usman, M., Spall, H. G. C. V., Greene, S. J., Pandey, A., McGuire, D. K., Ali, Z. A., Mentz, R. J., Fonarow, G. C., Spertus, J. A., Anker, S. D., et al. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00705-w · Cited by 64
“Nihilism” of chronic heart failure therapy in children and why effective therapy is withheld
Schranz, D., & Voelkel, N. F. (2016) · European Journal of Pediatrics · doi:10.1007/s00431-016-2700-3 · Cited by 57
“In adults with chronic HF, new therapeutic strategies like angiotensin-neprilysin inhibition have been lauded as a paradigm shift in HF therapy [30], while in children, the use of ACE inhib i tors , ß-adrenerg ic receptor b lockers , and mineralocorticoid-receptor blockers still remains controversial and—if recommende…”
BackgroundHeart Failure Clinical Trials in East and Southeast Asia
Mentz, R. J., Roessig, L., Greenberg, B., Sato, N., Shinagawa, K., Yeo, D., Kwok, B. W. K., Reyes, E. B., Krum, H., Pieske, B. M., et al. (2016) · JACC Heart Failure · doi:10.1016/j.jchf.2016.01.013 · Cited by 62
“fraction (EF) (5), including recent trials of sacubitril/valsartan (6) and ivabradine (7) therapy.”
InfluentialAchieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients
Bhatt, A. S., DeVore, A. D., DeWald, T. A., Swedberg, K. B., & Mentz, R. J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.563 · Cited by 63
Self-citationWang, C., Chopade, S. A., Guo, Y., Early, J. T., Tang, B., Wang, E., Hillmyer, M. A., Lodge, T. P., & Sun, C. C. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00569 · Cited by 61
Shanmuganathan, M., Vughs, J., Noseda, M., & Emanueli, C. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01159 · Cited by 60
“introduced in patients 3 years ago (McMurray et al., 2014).”
Smith, G. H., Shore, S., Allen, L. A., Markham, D. W., Mitchell, A. R., Moore, M., Morris, A. A., Speight, C. D., & Dickert, N. W. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010635 · Cited by 57
Norberg, H., Bergdahl, E., & Lindmark, K. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12251 · Cited by 61
“In the PARADIGM-HF trial, 12% of the patients withdrew during the run-in phase owing to adverse events of enalapril or sacubitril–valsartan.(10) A previous study from the Swedish Heart Failure Registry showed Table 1 Comparison of baseline characteristics between the Umeå cohort and the PARADIGM-HF study population”
MethodResultHeart Failure: A Class Review of Pharmacotherapy.
Shah, A. A., Gandhi, D., Srivastava, S., Shah, K. J., & Mansukhani, R. P. (2017) · PubMed · Cited by 75
Docherty, K. F., Campbell, R. T., Brooksbank, K. J. M., Dreisbach, J. G., Forsyth, P., Godeseth, R. L., Hopkins, T., Jackson, A. M., Lee, M. M. Y., McConnachie, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.054892 · Cited by 60
“Sacubitril/valsartan, compared with valsartan, increased plasma levels of ANP (P=0.013), midregional proadrenomedullin (P 0.001), GLP-1 (P 0.001), galectin-3 (P=0.045), and urinary cGMP (P=0.001).”
BackgroundInfluentialSelf-citationCentral and peripheral sympathetic activation in heart failure
Grassi, G. M., Mancia, G., & Esler, M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab222 · Cited by 57
Yoon, S., Makar, M. M., Kar, S., Chakravarty, T., Oakley, L. S., Sekhon, N., Koseki, K., Nakamura, M., Hamilton, M. A., Patel, J. K., et al. (2022) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2022.07.004 · Cited by 62
Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective
Ali, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alnaaim, S. A., Alexiou, A. T., Papadakis, M., Khalifa, A. A., Saad, H. M., & Batiha, G. E. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17993 · Cited by 61
“46 Evaluation of the ability of NEP inhibitors to cross BBB in patients with mild cognitive dysfunction and pre-AD is complex.”
BackgroundKosiborod, M., Cherney, D. Z. I., Desai, A. S., Testani, J. M., Verma, S., Chinnakondepalli, K., Dolling, D. I., Patel, S., Dahl, M., Eudicone, J. M., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.014 · Cited by 61
Self-citationVirgadamo, S., Charnigo, R., Darrat, Y., Morales, G., & Elayi, C. S. (2015) · World Journal of Cardiology · doi:10.4330/wjc.v7.i11.808 · Cited by 64
Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure
Ibrahim, N. E., & Januzzi, J. L. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.259564 · Cited by 64
Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy
Alonso, N., Moliner, P., & Mauricio, D. (2017) · Advances in experimental medicine and biology · doi:10.1007/5584_2017_105 · Cited by 59
Trivedi, R. K., Polhemus, D. J., Li, Z., Yoo, D., Koiwaya, H., Scarborough, A. L., Goodchild, T. T., & Lefer, D. J. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008268 · Cited by 61
“6 The clinical trial was halted early because of the signi fi cant bene fi t afforded to patients; however, there were serious limitations to the study that have been described at length in many opinion articles.”
Endothelial glycocalyx: Role in body fluid homeostasis and fluid management
Kundra, P., & Goswami, S. (2019) · Indian Journal of Anaesthesia · doi:10.4103/ija.ija_751_18 · Cited by 61
“However, for chronic heart failure where there is actual fluid retention, sodium restriction to less than 2 g/day, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitor, beta blockers and aldosterone antagonists along with diuretics can improve oedema and pr…”
Vitale, G., Romano, G., Franco, A. D., Caccamo, G., Nugara, C., Ajello, L., Storniolo, S., Sarullo, S., Agnese, V., Giallauria, F., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020262 · Cited by 59
“In the PARADIGM-HF trial [1], sacubitril/valsartan reduced the risk of death and hospitalization for HF in patients with HFrEF, as compared to enalapril; however, little is known on how sacubitril/valsartan influences cardiopulmonary function.”
BackgroundResultInfluentialAntihypertensive agents in Alzheimer’s disease: beyond vascular protection
Lebouvier, T., Chen, Y., Duriez, P., Pasquier, F., & Bordet, R. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1708195 · Cited by 55
“The first-in-class neprilysin inhibitor sacubitril was successfully tested in hypertension [107] and heart failure [108] in combination with the ARB enalapril.”
BackgroundRosselló, X., Ferreira, J. P., Pocock, S., McMurray, J. J. V., Solomon, S. D., Lam, C. S. P., Girerd, N., Pitt, B., Rossignol, P., & Zannad, F. M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1740 · Cited by 56
Self-citationSacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction
Mann, D. L., Greene, S. J., Givertz, M. M., Vader, J. M., Starling, R. C., Ambrosy, A. P., Shah, P. M., McNulty, S. E., Mahr, C., Gupta, D., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.05.005 · Cited by 57
Bao, J., Kan, R., Chen, J., Xuan, H., Wang, C., Li, D., & Xu, T. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105573 · Cited by 61
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Jiménez‐Marrero, S., Yun, S., Cainzos‐Achirica, M., Enjuanes, C., Garay, A., Farré, N., Verdú-Rotellar, J. M., Linas, A., Ruíz, P., Hidalgo, E., et al. (2018) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x18796439 · Cited by 59
“III–IV 56 (48) 30 (46) 26(52) LVEF, % 58 (10) 59 (11) 56 (10) Ischaemic cause of HF 37 (32) 21 (32) 16 (32) Comorbidities Hypertension 106 (91) 61 (92) 45 (90) Atrial fibrillation 57 (49) 32 (49) 25 (50) Diabetes mellitus 58 (50) 34 (52) 24 (48) CKD 71 (61) 41 (62) 30 (60) COPD 30 (26) 14 (21) 16 (32) Iron deficiency…”
Krittayaphong, R., & Permsuwan, U. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.017 · Cited by 59
Kario, K., Hoshide, S., Narita, K., Okawara, Y., Kanegae, H., Aoki, K., Kihara, H., Koga, T., Nakata, T., Oku, K., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18198 · Cited by 60
Causland, F. R. M., Lefkowitz, M. P., Claggett, B. L., Packer, M., Senni, M., Gori, M., Jhund, P. S., McGrath, M. M., Rouleau, J. L., Shi, V. C., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2421 · Cited by 60
Self-citationMolecular mechanisms of sacubitril/valsartan in cardiac remodeling
Mustafa, N. H., Jalil, J., Zainalabidin, S., Saleh, M. S. M., Asmadi, A. Y., & Kamisah, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.892460 · Cited by 65
“There is considerable evidence that shows that the secreted frizzled-related protein 1 (sFRP-1)/Wnt/β-catenin signaling pathway plays a role in TGF-β-mediated fibrosis in cardiac remodeling (Akhmetshina et al., 2012; McMurray et al., 2014).”
BackgroundFilippatos, G. S., Anker, S. D., Butler, J., Farmakis, D. T., Ferreira, J. P., Gollop, N. D., Brueckmann, M., Iwata, T., Pocock, S., Zannad, F. M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2707 · Cited by 58
Self-citationDASH Score and Subsequent Risk of Coronary Artery Disease: The Findings From Million Veteran Program
Djoussé, L., Ho, Y.-L. A., Nguyen, X. T., GAGNON, D. R., Wilson, P. W. F., Cho, K., Gaziano, J. M., Halasz, I., Federman, D. G., Beckham, J. C., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008089 · Cited by 60
Luo, N., O'Connor, C. M., Cooper, L. B., Sun, J.-L., Coles, A., Reed, S. D., Whellan, D. J., Piña, I. L., Kraus, W. E., & Mentz, R. J. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1299 · Cited by 54
Hyperuricemia: a novel old disorder—relationship and potential mechanisms in heart failure
Borghi, C., Palazzuoli, A., Landolfo, M., & Cosentino, E. R. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09869-z · Cited by 61
Correale, M., Mallardi, A., Mazzeo, P., Tricarico, L., Diella, C., Romano, V. C., Ferraretti, A., Leopizzi, A., Merolla, G., Biase, M. D., et al. (2020) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2020.100486 · Cited by 55
Pfeffer, M. A., Claggett, B. L., Lewis, E. F., Granger, C. B., Køber, L., Maggioni, A. P., Mann, D. L., McMurray, J. J. V., Rouleau, J. L., Solomon, S. D., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.057429 · Cited by 55
Self-citationPascual-Figal, D. A., Wachter, R., Senni, M., Bělohlávek, J., Noè, A., Carr, D., & Butylin, D. (2017) · ESC Heart Failure · doi:10.1002/ehf2.12246 · Cited by 58
“but in common with other major studies, it enrolled patients who were ambulatory at the time of inclusion.(38) The study population of the TITRATION study, which compared up-”
BackgroundResultInfluentialEffect of glucose-lowering therapies on heart failure
Nassif, M. E., & Kosiborod, M. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.211 · Cited by 55
Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
Kaplinsky, E., & Mallarkey, G. (2018) · Drugs in Context · doi:10.7573/dic.212518 · Cited by 54
“For example, significant improvements of morbidity and mortality have been obtained with angiotensin-converting enzyme inhibitors (ACEi), angiotensin-receptor blockers (ARB), β-blockers (BB) and mineralocorticoid receptor antagonists (MRA) [10,11].”
BackgroundDAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
Kaplinsky, E. (2020) · Drugs in Context · doi:10.7573/dic.2019-11-3 · Cited by 68
“The primary outcomes were (1) the average of mean NT-proBNP at 6 and 12 weeks and (2) a composite of the proportion of patients with a ≥5 point increase in HF health status on the KCCQ overall score or at least a 20% decrease in NT-proBNP.”
Yao, Y., Zhang, R., An, T., Zhao, X., & Zhang, J. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12844 · Cited by 57
“Besides dapagliflozin, the Prospective comparison of Angiotensin Receptor neprilysin inhibitors with Angiotensin converting enzyme inhibitors to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM‐HF) trial showed that another emerging drug, sacubitril–valsartan, effectively reduced the risk…”
BackgroundMüllens, W., Auricchio, A., Martens, P., Witte, K. K., Cowie, M., Delgado, V., Dickstein, K., Linde, C. M., Vernooy, K., Leyva, F., et al. (2020) · EP Europace · doi:10.1093/europace/euaa411 · Cited by 64
Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology
Petraina, A., Nogales, C., Krahn, T., Mucke, H. A., Lüscher, T. F., Fischmeister, R., Kass, D. A., Burnett, J. C. J., Hobbs, A. J., & Schmidt, H. H. H. W. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab240 · Cited by 58
McCullough, P. A., Mehta, H. S., Barker, C. M., Houten, J. V., Mollenkopf, S. A., Gunnarsson, C., Ryan, M., & Cork, D. P. (2021) · Clinical Cardiology · doi:10.1002/clc.23664 · Cited by 55
Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options
Sayın, B. Y., & Oto, A. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00260-y · Cited by 67
Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting
Lin, H., Geurts, F., Hassler, L., BATLLE, D. C., Colafella, K. M. M., Denton, K. M., Zhuo, J. L., Li, X. C., Ramkumar, N., Koizumi, M., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000236 · Cited by 60
“, 2016), in whom studies showed a substantial reduction in mortality and hospitalization (McMurray et al., 2014).”
BackgroundRosano, G. M. C., Teerlink, J. R., Kinugawa, K., Bayés‐Genís, A., Chioncel, O. D., Fang, J. C.-T., Greenberg, B., Ibrahim, N. E., Imamura, T., Inomata, T., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3646 · Cited by 72
Zannad, F. M., O’Connor, C. M., Butler, J., McMullan, C. J., Anstrom, K. J., Barash, I., Bonaca, M. P., Borentain, M., Corda, S., Gates, D. F., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01682-4 · Cited by 66
Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry
DeVore, A. D., Thomas, L. E., Albert, N. M., Butler, J., Hernandez, A. F., Patterson, J. H., Spertus, J. A., Williams, F. B., Turner, S. J., Chan, W. W., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.04.010 · Cited by 60
CSI position statement on management of heart failure in India
Guha, S., Harikrishnan, S., Ray, S., Sethi, R., Ramakrishnan, S., Banerjee, S., Bahl, V. K., Goswami, K. C., Banerjee, A. K., Shanmugasundaram, S., et al. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.05.003 · Cited by 65
“B Beta-blockers: Adding beta-blockers to standard treatment in patients with HF has demonstrated significant risk reduction of up to 30–40% in cardiovascular death, sudden death, hospitalization for worsening HF.137–139 Based on these data, beta-blockers are now accepted as a standard pharmacological treatment along w…”
BackgroundInfluential
Metadata
- Authors
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- Montreal Heart Institute (CA)
- Imperial College London (GB)
- Medical University of South Carolina (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-11
- Volume
- 371
- Issue
- 11
- Pages
- 993-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113698123
- Cited by
- 6,957
- References
- 30
- Citations by year
- 2026: 432 · 2025: 599 · 2024: 634 · 2023: 711 · 2022: 725 · 2021: 758 · 2020: 750 · 2019: 613 · 2018: 482 · 2017: 484 · 2016: 411 · 2015: 296 · 2014: 41
- FWCI
- 281.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- angiotensin receptor-neprilysin inhibition, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, heart failure symptoms, hypotension, angiotensin II receptor blockade, ACE inhibitors, renin-angiotensin system, heart failure prognosis, heart failure with preserved ejection fraction
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Tetrazoles, Neprilysin, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.